A61L2300/402

CYCLOOXYGENASE INHIBITOR AND CALCIUM CHANNEL ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN UROLOGICAL PROCEDURES
20220062252 · 2022-03-03 ·

Compositions of a cyclooxygenase inhibitor and a calcium channel antagonist in a liquid carrier. The composition may be administered the the urinary tract during urological diagnostic, interventional, surgical and other medical procedures. One disclosed composition comprises ketoprofen and nifedipine in a liquid irrigation carrier, and includes a solubilizing agent, stabilizing agents and a buffering agent.

Ready-to-use esthetic compositions
11235087 · 2022-02-01 · ·

Described are ready-to-use injectable compositions comprising polymeric microspheres or microparticles of non-animal origin, a hydrogel comprising water and a cellulose-derivative gelling agent, and polysorbate 80. Further described are methods of using the ready-to-use injectable compositions for reparative or plastic surgery, esthetic dermatology, facial contouring, body contouring, and gingival augmentation.

BIORESORBABLE BIOLOGICAL MATRIX FOR REPAIRING BONE TISSUE DEFECTS AND METHOD FOR THE PRODUCTION THEREOF

The invention relates to medical biotechnology, medicine, traumatology, orthopedics, dentistry, and orthodontics. A method is proposed for producing a biological matrix intended for the repairing of bone tissue defects; said method may include a plurality of consecutive stages, such as pre-treating biological material, coarse filtering and fractionating, fine filtering and extracting, delipidizing, fermenting, demineralizing, and sterilizing in supercritical fluid. The resulting bioresorbable biological matrix is characterized by increased osteo- and biointegration, an optimal biodegradation rate, high biocompatibility, an absence of recipient immunoreactivity, high osteoconduction capacity, and pronounced osteogenic potential in osteosynthesis and bone grafting. The matrix consists of ossein, hydroxyapatite and/or calcium phosphate, wherein the ossein is in native unreduced form with its three-dimensional structure completely intact, the hydroxyapatite and calcium phosphate are in native amorphous form, and the matrix itself, from which cellular debris, foreign lipids, nucleic acids, and immunogens have been removed, contains residual amounts of bone morphogenetic proteins and is impregnated with vesicular phosphatidylcholine and/or cholesterol containing gelatin (hydrolyzed collagen), and/or bone atelocollagen, and/or poly-(ε-caprolactone) and additionally containing biologically active substances (including bioactive peptides and growth factors).

Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof

The present invention provides threads of hyaluronic acid, and/or derivatives thereof, methods of making thereof and uses thereof, for example, in aesthetic applications (e.g., dermal fillers), surgery (sutures), drug delivery, etc.

Hyaluronic acid composition
11154481 · 2021-10-26 · ·

An injectable hyaluronic acid composition including a hyaluronic acid; a local anesthetic selected from the group of amide and ester type local anesthetics or a combination thereof; and an ascorbic acid derivative in an amount which prevents or reduces the effect on the viscosity and/or elastic modulus G′ of the composition caused by the local anesthetic upon sterilization by heat. Further, the medical and non-medical, such as cosmetic, use of such a composition, and to a method of manufacturing such a composition.

Magneto-Patterned-Cell-Laden Hydrogel Materials and Methods of Making and Using Same

The present disclosure is concerned with magneto-patterned cell-laden hydrogel materials and methods of making and using those materials. The disclosed materials are useful for, among other things, repair of tissue defects, e.g., tissue at a tissue interface such as a bone-cartilage interface.

HYDROGEL COMPOSITIONS ENCAPSULATING SOLID PARTICLES

The present disclosure relates to compositions comprising hydrogels and solid particles and their use. More specifically, the proposed technique relates to methods for manufacturing of a composition comprising solid particles encapsulated within crosslinked polysaccharide molecules forming hydrogel particles, the method comprising mixing water-soluble polysaccharide molecules comprising one or more carboxyl groups, water insoluble solid particles, a di- or multinucleophilic functional crosslinker, and a coupling agent, in a water suspension at pH between 5 and 9, to form a composition comprising a hydrogel of crosslinked polysaccharide molecules encapsulating the solid particles. The disclosure comprises the composition, methods for producing the composition and use of the composition as a dermal filler.

POLYMER IMPLANTS

The present technology relates to polymer implants. In some embodiments, the polymer implant may have a volume having minimum cross-sectional dimension of 400 μm. The polymer implant may be configured to be implanted within a mammalian body for at least 3 days without undergoing core acidification.

CYCLOOXYGENASE INHIBITOR AND CALCIUM CHANNEL ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN UROLOGICAL PROCEDURES
20210290605 · 2021-09-23 ·

Compositions of a cyclooxygenase inhibitor and a calcium channel antagonist in a liquid carrier. The composition may be administered the urinary tract during urological diagnostic, interventional, surgical and other medical procedures. One disclosed composition comprises ketoprofen and nifedipine in a liquid irrigation carrier, and includes a solubilizing agent, stabilizing agents and a buffering agent.

HYALURONIC ACID-BASED GELS INCLUDING LIDOCAINE
20210283313 · 2021-09-16 ·

Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.